Biologic Response Modifiers and Pediatric Psoriasis

Publisher： John Wiley & Sons Inc

E-ISSN： 1525-1470|32|3|303-320

ISSN： 0736-8046

Source： PEDIATRIC DERMATOLOGY, Vol.32, Iss.3, 2015-05, pp. : 303-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis

By Bonafede Machaon   Joseph George J.   Princic Nicole   Harrison David J.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1120-1128

Informa Healthcare

Access to resources Recommend Favorite

In vitro affinity reduction of biologic response modifiers from production buffy coat platelets exposed to recombinant protein receptors

By  

TRANSFUSION, Vol. 55, Iss. 8, 2015-08 ,pp. : 1919-1926

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biologic Therapy in Psoriasis: Safety Profile

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 4-11

Bentham Science Publishers

Access to resources Recommend Favorite

Pediatric pustular psoriasis with Turner's syndrome

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 12, 2015-12 ,pp. : 1208-1209

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment Heterogeneity in Asthma: Genetics of Response to Leukotriene Modifiers

By Lima John J.  

Molecular Diagnosis & Therapy, Vol. 11, Iss. 2, 2007-01 ,pp. : 97-104

Adis International

Access to resources Recommend Favorite